Compounds / Metabolic / Cagrilintide

Cagrilintide

Cagrilintide (Long-Acting Amylin Receptor Agonist — AM833)
MetabolicWell ResearchedFDA: Not approved; Phase III trials ongoing

Overview

Phase III CagriSema (+ semaglutide): ~25% weight loss — additive effect beyond either agent alone. Developed by Novo Nordisk.

Mechanism of Action

Long-acting amylin receptor agonist (acylated amylin analog). Activates central amylin receptors for satiety and gastric emptying slowdown. Complements GLP-1 via different receptor system.

Pharmacokinetics

Half-life
7.5 days
Peak (Tmax)
2 days
Cleared
~37.5 days

Molecular Profile

Molecular weight
4,409.01 Da
CAS number
2381002-76-2
Type
Amylin receptor agonist
Length
37 amino acids

Key Research Findings

Amylin receptor agonism; ~25% weight loss with semaglutide combination (CagriSema Phase III).

Published Research

Lancet (2021)
Enebo LB et al. Safety, tolerability, pharmacokinetics of cagrilintide
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideMazdutideBioglutideAOD-9604
Clinical Guidance

Research data is not a treatment plan. If you are considering Cagrilintide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Cagrilintide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals